FDA awards priority review to Genmab and Abbvie's cancer candidate
Potential cancer treatment epcoritamab will now be reviewed under the US Food and Drug Administration’s accelerated pathway.
by marketwire, translated by daniel pedersen
The road to market ahead of Genmab’s cancer candidate, epcoritamab, has just gotten shorter after the US Food and Drug Administration, FDA, has decided to accelerate review, a company press release announces.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.